Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
United Biomedical, Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to one examiner and one art unit, creating a focused prosecution path.
LOCKARD, JON MCCLELLAND is the identified examiner. Counsel can concentrate its review on that examiner’s record and the relevant biotechnology assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 1 | 74.4% | +27.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794720 | PEPTIDE IMMUNOGENS TARGETING PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE | LOCKARD, JON MCCLELLAND | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17794720 | PEPTIDE IMMUNOGENS TARGETING PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnited Biomedical, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jon Mcclelland Lockard has the most, with 1 of United Biomedical, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
